{"id":"NCT02277691","sponsor":"Takeda","briefTitle":"A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension","officialTitle":"A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-07","primaryCompletion":"2016-04-25","completion":"2016-04-25","firstPosted":"2014-10-29","resultsPosted":"2017-06-26","lastUpdate":"2017-08-02"},"enrollment":341,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"TAK-536TCH tablet","otherNames":[]},{"type":"DRUG","name":"TAK-536CCB tablet","otherNames":[]},{"type":"DRUG","name":"HCTZ 12.5 mg tablet","otherNames":[]}],"arms":[{"label":"TAK-536TCH","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.","primaryOutcome":{"measure":"Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline up to Week 52","effectByArm":[{"arm":"TAK-536TCH","deltaMin":289,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["Japan"]},"refs":{"pmids":["29235365"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":341},"commonTop":["Nasopharyngitis","Blood uric acid increased","Eczema","Hyperuricaemia","Back pain"]}}